Which has preferable earnings and valuation, ATHE or ZNTL?

Alterity Therapeutics has higher earnings, but lower revenue than Zentalis Pharmaceuticals. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Alterity Therapeutics N/A N/A -$15.88M N/A N/A Zentalis Pharmaceuticals $67.43M 3.22 -$137.06M -$1.95 N/A

Is ATHE or ZNTL more profitable?

Alterity Therapeutics' return on equity of 0.00% beat Zentalis Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Alterity Therapeutics N/A N/A N/A Zentalis Pharmaceuticals N/A -70.18% -51.46%

Does the media prefer ATHE or ZNTL?

In the previous week, Zentalis Pharmaceuticals had 1 more articles in the media than Alterity Therapeutics. MarketBeat recorded 3 mentions for Zentalis Pharmaceuticals and 2 mentions for Alterity Therapeutics. Alterity Therapeutics' average media sentiment score of 0.33 beat Zentalis Pharmaceuticals' score of 0.17 indicating that Alterity Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alterity Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Zentalis Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend ATHE or ACB?

Alterity Therapeutics presently has a consensus target price of $10.00, suggesting a potential upside of 164.55%. Given Alterity Therapeutics' stronger consensus rating and higher probable upside, equities analysts clearly believe Alterity Therapeutics is more favorable than Aurora Cannabis. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Alterity Therapeutics 1 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.57 Aurora Cannabis 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.50

Which has stronger valuation and earnings, ATHE or ACB?

Alterity Therapeutics has higher earnings, but lower revenue than Aurora Cannabis. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Alterity Therapeutics N/A N/A -$15.88M N/A N/A Aurora Cannabis $247.82M 1.05 -$88.13M -$1.41 N/A

Does the media refer more to ATHE or ACB?

In the previous week, Aurora Cannabis had 3 more articles in the media than Alterity Therapeutics. MarketBeat recorded 5 mentions for Aurora Cannabis and 2 mentions for Alterity Therapeutics. Alterity Therapeutics' average media sentiment score of 0.33 beat Aurora Cannabis' score of 0.18 indicating that Alterity Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alterity Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Aurora Cannabis 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 2 Very Negative mention(s) Neutral

Which has better valuation & earnings, CRDL or ATHE?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cardiol Therapeutics N/A N/A -$24.20M -$0.25 N/A Alterity Therapeutics N/A N/A -$15.88M N/A N/A

Is CRDL or ATHE more profitable?

Alterity Therapeutics' return on equity of 0.00% beat Cardiol Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Cardiol Therapeutics N/A -180.44% -140.28% Alterity Therapeutics N/A N/A N/A

Does the media refer more to CRDL or ATHE?

In the previous week, Cardiol Therapeutics had 2 more articles in the media than Alterity Therapeutics. MarketBeat recorded 4 mentions for Cardiol Therapeutics and 2 mentions for Alterity Therapeutics. Cardiol Therapeutics' average media sentiment score of 0.62 beat Alterity Therapeutics' score of 0.33 indicating that Cardiol Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cardiol Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Alterity Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate SIGA or ATHE?

Alterity Therapeutics has a consensus price target of $10.00, indicating a potential upside of 164.55%. Given Alterity Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Alterity Therapeutics is more favorable than Siga Technologies. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Siga Technologies 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Alterity Therapeutics 1 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.57

Which has stronger valuation & earnings, SIGA or ATHE?

Siga Technologies has higher revenue and earnings than Alterity Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Siga Technologies $94.57M 2.40 $23.28M -$0.05 N/A Alterity Therapeutics N/A N/A -$15.88M N/A N/A

Do analysts prefer ATHE or SBTX?

Alterity Therapeutics presently has a consensus price target of $10.00, suggesting a potential upside of 164.55%. Given Alterity Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Alterity Therapeutics is more favorable than Silverback Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Alterity Therapeutics 1 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.57 Silverback Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has better earnings and valuation, ATHE or SBTX?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Alterity Therapeutics N/A N/A -$15.88M N/A N/A Silverback Therapeutics N/A N/A -$89.48M -$2.42 N/A

Is ATHE or SBTX more profitable?

Alterity Therapeutics' return on equity of 0.00% beat Silverback Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Alterity Therapeutics N/A N/A N/A Silverback Therapeutics N/A -29.62% -28.20%

Alterity Therapeutics (ATHE) Competitors

$3.78 -0.13 (-3.32%)

As of 04:00 PM Eastern

Compare

ATHE vs. ZNTL, ACB, CRDL, SIGA, and SBTX

Should you buy Alterity Therapeutics stock or one of its competitors? Alterity Therapeutics's main competitors and comparable companies include Zentalis Pharmaceuticals (ZNTL), Aurora Cannabis (ACB), Cardiol Therapeutics (CRDL), Siga Technologies (SIGA), and Silverback Therapeutics (SBTX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Alterity Therapeutics compare to Zentalis Pharmaceuticals?

Alterity Therapeutics (NASDAQ:ATHE) and Zentalis Pharmaceuticals (NASDAQ:ZNTL) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, media sentiment, earnings, analyst recommendations, valuation, risk, dividends and institutional ownership.

Alterity Therapeutics' return on equity of 0.00% beat Zentalis Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alterity Therapeutics	N/A	N/A	N/A
Zentalis Pharmaceuticals	N/A	-70.18%	-51.46%

Alterity Therapeutics currently has a consensus target price of $10.00, indicating a potential upside of 164.55%. Zentalis Pharmaceuticals has a consensus target price of $6.75, indicating a potential upside of 122.77%. Given Alterity Therapeutics' stronger consensus rating and higher possible upside, equities analysts clearly believe Alterity Therapeutics is more favorable than Zentalis Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alterity Therapeutics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57
Zentalis Pharmaceuticals	1 Sell rating(s)	4 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.40

In the previous week, Zentalis Pharmaceuticals had 1 more articles in the media than Alterity Therapeutics. MarketBeat recorded 3 mentions for Zentalis Pharmaceuticals and 2 mentions for Alterity Therapeutics. Alterity Therapeutics' average media sentiment score of 0.33 beat Zentalis Pharmaceuticals' score of 0.17 indicating that Alterity Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Alterity Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Zentalis Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Alterity Therapeutics has higher earnings, but lower revenue than Zentalis Pharmaceuticals.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alterity Therapeutics	N/A	N/A	-$15.88M	N/A	N/A
Zentalis Pharmaceuticals	$67.43M	3.22	-$137.06M	-$1.95	N/A

2.1% of Alterity Therapeutics shares are owned by institutional investors. 38.8% of Alterity Therapeutics shares are owned by company insiders. Comparatively, 3.8% of Zentalis Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Alterity Therapeutics has a beta of 0.27, meaning that its stock price is 73% less volatile than the broader market. Comparatively, Zentalis Pharmaceuticals has a beta of 1.85, meaning that its stock price is 85% more volatile than the broader market.

Summary

Alterity Therapeutics beats Zentalis Pharmaceuticals on 8 of the 11 factors compared between the two stocks.

How does Alterity Therapeutics compare to Aurora Cannabis?

Alterity Therapeutics (NASDAQ:ATHE) and Aurora Cannabis (NASDAQ:ACB) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, institutional ownership, analyst recommendations, media sentiment, earnings, profitability, valuation and dividends.

In the previous week, Aurora Cannabis had 3 more articles in the media than Alterity Therapeutics. MarketBeat recorded 5 mentions for Aurora Cannabis and 2 mentions for Alterity Therapeutics. Alterity Therapeutics' average media sentiment score of 0.33 beat Aurora Cannabis' score of 0.18 indicating that Alterity Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Alterity Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Aurora Cannabis	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	2 Very Negative mention(s)	Neutral

Alterity Therapeutics has higher earnings, but lower revenue than Aurora Cannabis.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alterity Therapeutics	N/A	N/A	-$15.88M	N/A	N/A
Aurora Cannabis	$247.82M	1.05	-$88.13M	-$1.41	N/A

2.1% of Alterity Therapeutics shares are held by institutional investors. Comparatively, 47.6% of Aurora Cannabis shares are held by institutional investors. 38.8% of Alterity Therapeutics shares are held by company insiders. Comparatively, 0.0% of Aurora Cannabis shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Alterity Therapeutics presently has a consensus target price of $10.00, suggesting a potential upside of 164.55%. Given Alterity Therapeutics' stronger consensus rating and higher probable upside, equities analysts clearly believe Alterity Therapeutics is more favorable than Aurora Cannabis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alterity Therapeutics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57
Aurora Cannabis	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50

Alterity Therapeutics has a net margin of 0.00% compared to Aurora Cannabis' net margin of -32.26%. Aurora Cannabis' return on equity of 4.37% beat Alterity Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alterity Therapeutics	N/A	N/A	N/A
Aurora Cannabis	-32.26%	4.37%	3.45%

Alterity Therapeutics has a beta of 0.27, suggesting that its stock price is 73% less volatile than the broader market. Comparatively, Aurora Cannabis has a beta of 0.63, suggesting that its stock price is 37% less volatile than the broader market.

Summary

Alterity Therapeutics and Aurora Cannabis tied by winning 7 of the 14 factors compared between the two stocks.

How does Alterity Therapeutics compare to Cardiol Therapeutics?

Cardiol Therapeutics (NASDAQ:CRDL) and Alterity Therapeutics (NASDAQ:ATHE) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, media sentiment, profitability, risk, analyst recommendations, dividends, institutional ownership and valuation.

Alterity Therapeutics' return on equity of 0.00% beat Cardiol Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cardiol Therapeutics	N/A	-180.44%	-140.28%
Alterity Therapeutics	N/A	N/A	N/A

Cardiol Therapeutics has a beta of 0.79, meaning that its stock price is 21% less volatile than the broader market. Comparatively, Alterity Therapeutics has a beta of 0.27, meaning that its stock price is 73% less volatile than the broader market.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cardiol Therapeutics	N/A	N/A	-$24.20M	-$0.25	N/A
Alterity Therapeutics	N/A	N/A	-$15.88M	N/A	N/A

In the previous week, Cardiol Therapeutics had 2 more articles in the media than Alterity Therapeutics. MarketBeat recorded 4 mentions for Cardiol Therapeutics and 2 mentions for Alterity Therapeutics. Cardiol Therapeutics' average media sentiment score of 0.62 beat Alterity Therapeutics' score of 0.33 indicating that Cardiol Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cardiol Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Alterity Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

12.5% of Cardiol Therapeutics shares are owned by institutional investors. Comparatively, 2.1% of Alterity Therapeutics shares are owned by institutional investors. 5.3% of Cardiol Therapeutics shares are owned by insiders. Comparatively, 38.8% of Alterity Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Cardiol Therapeutics presently has a consensus target price of $10.00, indicating a potential upside of 437.63%. Alterity Therapeutics has a consensus target price of $10.00, indicating a potential upside of 164.55%. Given Cardiol Therapeutics' higher probable upside, equities analysts plainly believe Cardiol Therapeutics is more favorable than Alterity Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cardiol Therapeutics	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Alterity Therapeutics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57

Summary

Alterity Therapeutics beats Cardiol Therapeutics on 6 of the 11 factors compared between the two stocks.

How does Alterity Therapeutics compare to Siga Technologies?

Siga Technologies (NASDAQ:SIGA) and Alterity Therapeutics (NASDAQ:ATHE) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, profitability, dividends, media sentiment, analyst recommendations, valuation, risk and institutional ownership.

Alterity Therapeutics has a consensus price target of $10.00, indicating a potential upside of 164.55%. Given Alterity Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Alterity Therapeutics is more favorable than Siga Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Siga Technologies	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Alterity Therapeutics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57

Siga Technologies has a beta of 0.97, indicating that its share price is 3% less volatile than the broader market. Comparatively, Alterity Therapeutics has a beta of 0.27, indicating that its share price is 73% less volatile than the broader market.

Alterity Therapeutics has a net margin of 0.00% compared to Siga Technologies' net margin of -5.19%. Alterity Therapeutics' return on equity of 0.00% beat Siga Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Siga Technologies	-5.19%	-1.55%	-1.32%
Alterity Therapeutics	N/A	N/A	N/A

55.4% of Siga Technologies shares are owned by institutional investors. Comparatively, 2.1% of Alterity Therapeutics shares are owned by institutional investors. 2.7% of Siga Technologies shares are owned by company insiders. Comparatively, 38.8% of Alterity Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

In the previous week, Alterity Therapeutics had 2 more articles in the media than Siga Technologies. MarketBeat recorded 2 mentions for Alterity Therapeutics and 0 mentions for Siga Technologies. Siga Technologies' average media sentiment score of 0.92 beat Alterity Therapeutics' score of 0.33 indicating that Siga Technologies is being referred to more favorably in the media.

Company	Overall Sentiment
Siga Technologies	Positive
Alterity Therapeutics	Neutral

Siga Technologies has higher revenue and earnings than Alterity Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Siga Technologies	$94.57M	2.40	$23.28M	-$0.05	N/A
Alterity Therapeutics	N/A	N/A	-$15.88M	N/A	N/A

Summary

Alterity Therapeutics beats Siga Technologies on 8 of the 13 factors compared between the two stocks.

How does Alterity Therapeutics compare to Silverback Therapeutics?

Alterity Therapeutics (NASDAQ:ATHE) and Silverback Therapeutics (NASDAQ:SBTX) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, media sentiment, risk, earnings, institutional ownership, analyst recommendations, valuation and profitability.

Alterity Therapeutics presently has a consensus price target of $10.00, suggesting a potential upside of 164.55%. Given Alterity Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Alterity Therapeutics is more favorable than Silverback Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alterity Therapeutics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57
Silverback Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Alterity Therapeutics' return on equity of 0.00% beat Silverback Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alterity Therapeutics	N/A	N/A	N/A
Silverback Therapeutics	N/A	-29.62%	-28.20%

Alterity Therapeutics has a beta of 0.27, suggesting that its share price is 73% less volatile than the broader market. Comparatively, Silverback Therapeutics has a beta of 0.6, suggesting that its share price is 40% less volatile than the broader market.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alterity Therapeutics	N/A	N/A	-$15.88M	N/A	N/A
Silverback Therapeutics	N/A	N/A	-$89.48M	-$2.42	N/A

In the previous week, Alterity Therapeutics had 2 more articles in the media than Silverback Therapeutics. MarketBeat recorded 2 mentions for Alterity Therapeutics and 0 mentions for Silverback Therapeutics. Alterity Therapeutics' average media sentiment score of 0.33 beat Silverback Therapeutics' score of 0.00 indicating that Alterity Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Alterity Therapeutics	Neutral
Silverback Therapeutics	Neutral

2.1% of Alterity Therapeutics shares are held by institutional investors. Comparatively, 74.9% of Silverback Therapeutics shares are held by institutional investors. 38.8% of Alterity Therapeutics shares are held by insiders. Comparatively, 34.4% of Silverback Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

Alterity Therapeutics beats Silverback Therapeutics on 9 of the 11 factors compared between the two stocks.

Get Alterity Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ATHE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ATHE vs. The Competition

Export

Metric	Alterity Therapeutics	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$70.87M	$12.53B	$7.26B	$12.97B
Dividend Yield	N/A	2.64%	2.53%	12.80%
P/E Ratio	N/A	789.79	274.69	25.77
Price / Sales	N/A	753.31	647.74	90.25
Price / Cash	N/A	15.08	28.04	34.72
Price / Book	2.36	10.57	10.56	6.36
Net Income	-$15.88M	$2.82B	$3.49B	$358.17M
7 Day Performance	-2.07%	-0.36%	-0.23%	0.54%
1 Month Performance	-19.06%	-1.19%	-2.80%	-2.95%
1 Year Performance	-15.63%	4.01%	18.25%	6.08%

Alterity Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ATHE Alterity Therapeutics	3.279 of 5 stars	$3.78 -3.3%	$10.00 +164.6%	-12.7%	$70.87M	N/A	N/A	11
ZNTL Zentalis Pharmaceuticals	3.5443 of 5 stars	$3.13 -10.6%	$6.75 +115.7%	+104.6%	$250.85M	$67.43M	N/A	106
ACB Aurora Cannabis	1.0979 of 5 stars	$3.82 +0.3%	N/A	-24.0%	$247.05M	$247.82M	N/A	1,028
CRDL Cardiol Therapeutics	2.7212 of 5 stars	$1.85 -7.0%	$10.00 +440.5%	+67.4%	$231.19M	N/A	N/A	18
SIGA Siga Technologies	0.7313 of 5 stars	$2.98 -5.4%	N/A	-64.2%	$226.33M	$94.57M	N/A	49	News Coverage

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ATHE) was last updated on 9/21/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Alterity Therapeutics (ATHE) Competitors

ATHE vs. ZNTL, ACB, CRDL, SIGA, and SBTX

How does Alterity Therapeutics compare to Zentalis Pharmaceuticals?

Summary

How does Alterity Therapeutics compare to Aurora Cannabis?

Summary

How does Alterity Therapeutics compare to Cardiol Therapeutics?

Summary

How does Alterity Therapeutics compare to Siga Technologies?

Summary

How does Alterity Therapeutics compare to Silverback Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ATHE vs. The Competition

Alterity Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Alterity Therapeutics (ATHE) Competitors

ATHE vs. ZNTL, ACB, CRDL, SIGA, and SBTX

How does Alterity Therapeutics compare to Zentalis Pharmaceuticals?

Is ATHE or ZNTL more profitable?

Do analysts recommend ATHE or ZNTL?

Does the media prefer ATHE or ZNTL?

Which has preferable earnings and valuation, ATHE or ZNTL?

Do institutionals & insiders have more ownership in ATHE or ZNTL?

Which has more volatility & risk, ATHE or ZNTL?

Summary

How does Alterity Therapeutics compare to Aurora Cannabis?

Does the media refer more to ATHE or ACB?

Which has stronger valuation and earnings, ATHE or ACB?

Do institutionals & insiders believe in ATHE or ACB?

Do analysts recommend ATHE or ACB?

Is ATHE or ACB more profitable?

Which has more risk & volatility, ATHE or ACB?

Summary

How does Alterity Therapeutics compare to Cardiol Therapeutics?

Is CRDL or ATHE more profitable?

Which has more risk & volatility, CRDL or ATHE?

Which has better valuation & earnings, CRDL or ATHE?

Does the media refer more to CRDL or ATHE?

Do institutionals and insiders have more ownership in CRDL or ATHE?

Do analysts rate CRDL or ATHE?

Summary

How does Alterity Therapeutics compare to Siga Technologies?

Do analysts rate SIGA or ATHE?

Which has more risk and volatility, SIGA or ATHE?

Is SIGA or ATHE more profitable?

Do institutionals & insiders believe in SIGA or ATHE?

Does the media favor SIGA or ATHE?

Which has stronger valuation & earnings, SIGA or ATHE?

Summary

How does Alterity Therapeutics compare to Silverback Therapeutics?

Do analysts prefer ATHE or SBTX?

Is ATHE or SBTX more profitable?

Which has more risk and volatility, ATHE or SBTX?

Which has better earnings and valuation, ATHE or SBTX?

Does the media prefer ATHE or SBTX?

Do insiders and institutionals hold more shares of ATHE or SBTX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ATHE vs. The Competition

Alterity Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools